Feb 08, 2024 / 03:30PM GMT
Vamil Divan - Guggenheim Securities, LLC - Analyst
All right. And I think we're ready to get going here with our next session. And thank everyone again for joining us for the Guggenheim Biotech Conference this year and for day two and next up in this room, we have a and I pharmaceuticals to I'm Vamil Divan by the way, if you don't know me on the pharma and U.S. biopharma analyst here joined up here by nickel. Wondering who's the President and CEO of eOn aaiPharma. Thanks so much for for joining us today, and we're going to do a fireside chat format so I have some questions. I'm going to go through. If anyone in the audience want to ask a question, please raise your hand and we can get your question in a well, but I'm maybe just for people who may be a little bit newer to the story around a farm, obviously been a pretty exciting times last couple couple of years here. And if you just sort of give an overview of the Company, the key sort of business segments that you're focused on. And so the key metrics in terms of recent performance I know you haven't reported Q4 yet, but just at least through the third
ANI Pharmaceuticals Inc at Guggenheim Healthcare Talks Transcript
Mar 03, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers